Free Trial
NASDAQ:GMTX

Gemini Therapeutics (GMTX) Stock Price, News & Analysis

Gemini Therapeutics logo
$49.51 -0.17 (-0.34%)
As of 05/2/2025

About Gemini Therapeutics Stock (NASDAQ:GMTX)

Key Stats

Today's Range
$49.20
$50.66
50-Day Range
$34.28
$56.92
52-Week Range
$1.16
$14.10
Volume
202,082 shs
Average Volume
189,291 shs
Market Capitalization
$2.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Receive GMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gemini Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GMTX Stock News Headlines

Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
See More Headlines

GMTX Stock Analysis - Frequently Asked Questions

Gemini Therapeutics' stock was trading at $63.40 at the start of the year. Since then, GMTX stock has decreased by 21.9% and is now trading at $49.51.
View the best growth stocks for 2025 here
.

Gemini Therapeutics, Inc. (NASDAQ:GMTX) released its quarterly earnings results on Monday, November, 15th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.04.

Shares of GMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Gemini Therapeutics investors own include Alphabet (GOOG), Meta Platforms (META), NVIDIA (NVDA), Zoom Video Communications (ZM), Activision Blizzard (ATVI), Fiverr International (FVRR) and Shopify (SHOP).

Company Calendar

Last Earnings
11/15/2021
Today
5/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GMTX
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-71,870,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.89 per share
Price / Book
17.13

Miscellaneous

Free Float
37,739,000
Market Cap
$2.15 billion
Optionable
Not Optionable
Beta
-0.12
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:GMTX) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners